Hosted by Quanticate · 🇺🇸 US · EN-GB · 51 episodes
Established thought leaders with verified media credentials.
QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.
Quanticate hosts QCast: Data-Driven Dialogue in Drug Development, a science show with 51 episodes published.
In this QCast episode, Jullia and Tom discuss the Global Statistical Test for multiple endpoints analysis and why it can be useful when a clinical trial needs to assess more than one outcome at the same time. They cover
In this QCast episode, Jullia and Tom discuss CDASH standards and conformance in clinical data management, with a focus on where CDASH sits in the clinical data flow and why it matters before data reaches SDTM. The episo
In this QCast episode, Jullia and Tom discuss multi-omics and its application in personalised medicine studies. The episode explains how genomic, transcriptomic, proteomic, metabolomic and other biological data layers ca
In this QCast episode, Jullia and Tom discuss BIMO listings and their role in FDA inspection readiness. They explain how Bioresearch Monitoring looks at clinical trial conduct, participant protection, data credibility, a
In this QCast episode, Jullia and Tom discuss efficacy endpoints in oncology clinical trials and why endpoint choice shapes how treatment benefit is assessed. They look at overall survival, progression-free survival, obj
In this QCast episode, Jullia and Tom discuss how ADaM datasets are created for pharmacokinetic, or PK, analysis. They look at the role of ADPC for concentration data and ADPP for derived PK parameters, including how the
In this QCast episode, Jullia and Tom discuss clinical data review as an active part of study oversight, rather than a late-stage clean-up exercise. They explore how timely, connected review supports subject safety, data
In this QCast episode, Jullia and Tom discuss clinical trial management systems and their role in keeping clinical studies under control. They explain how CTMS differs from EDC, why operational visibility matters across
In this QCast episode, co-hosts Jullia and Tom explore clinical trial simulation and how it supports better study design decisions before a trial begins. They explain how simulation uses statistical and mathematical mode
In this QCast episode, co-hosts Jullia and Tom explore clinical study start up and why it has such a direct effect on how a trial runs once sites begin opening. They look at what study start up actually includes, from fe
In this QCast episode, Jullia and Tom explore medical device clinical trials and why they differ in important ways from drug studies. They explain what these trials are designed to show, how safety, performance, and clin
In this QCast episode, Jullia and Tom explore SAD and MAD studies and why they play such a central role in early clinical development. They explain what single ascending dose and multiple ascending dose studies are desig
In this QCast episode, Jullia and Tom explore functional service provision and why it remains such an important outsourcing model in clinical development. They explain what FSP means in practical terms, how it differs fr
In this QCast episode, Jullia and Tom explore automation in clinical trials and why it matters for modern study delivery. They explain what automation looks like in day-to-day trial work, where it can reduce manual burde
In this QCast episode, Jullia and Tom explore observational studies and why they remain such an important part of the evidence base in drug development. They explain what makes an observational study different from an in
In this QCast episode, Jullia and Tom explore phase 2b in clinical trials and why this stage plays such a decisive role in moving a programme towards phase 3. They explain how phase 2b is typically used to reduce uncerta
In this QCast episode, Jullia and Tom unpack ACR response criteria in rheumatoid arthritis clinical trials and why these endpoints are more operationally demanding than they look on paper. They explain what ACR20, ACR50,
In this QCast episode, Jullia and Tom explore regulatory submissions in clinical trials and why strong submission discipline protects timelines long before any scientific review begins. They discuss what a regulatory sub
In this QCast episode, Jullia and Tom unpack therapeutic areas in clinical research and why they matter far beyond a clinical label. They discuss how a therapeutic area shapes trial design assumptions, from endpoint sele
In this QCast episode, Jullia and Tom break down eCRF design in clinical trials and why it has such an outsized impact on data quality, site workload, and downstream analysis. They clarify what an electronic case report
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
QCast: Data-Driven Dialogue in Drug Development has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
QCast: Data-Driven Dialogue in Drug Development is hosted by Quanticate. The show is categorised under science (life) and has published 51 episodes.
QCast: Data-Driven Dialogue in Drug Development has published 51 episodes.
QCast: Data-Driven Dialogue in Drug Development regularly covers science, life. It sits in the science category, with a life focus.
QCast: Data-Driven Dialogue in Drug Development is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
QCast: Data-Driven Dialogue in Drug Development hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of QCast: Data-Driven Dialogue in Drug Development average 11 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates QCast: Data-Driven Dialogue in Drug Development's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 9 days ago.
